With a rapidly ageing population in Singapore, the prevalence of dementia is expected to increase to 53,000 by 2020 and to further increase to 187,000 by 2050. The MACC aims to develop novel scientific insights and advances in the understanding of dementia and cognitive impairment leading to interventions that can prolong independent community function, delay institutionalization and therefore lower healthcare expenditure for patients suffering from dementia. The MACC has been supported by a Centre Grant(CG) from the NMRC since 2010.
MACC owns a team experienced clinicians, psychometric raters and research coordinators, who have the expertise to design, initiate and carry out complex studies and clinical drug trials in multi-ethnic cognitive impaired or demented population.
The MACC research facilities – the MACC Assessment unit is equipped with comfortable assessment rooms with tools, devices & equipment for the conduct of various assessments ranging from clinical, neuropsychological and retinal eye imaging. MACC’s full BSL2 laboratory is located in MD 6. We have an active collaboration with CIRC for its 3T MRI facilities and PET Imaging.
Connie Teo Kee Ling